

↳ 4th Symposium on Novel Targeting Drugs and Radiotherapy
From the Bench to the Clinic

10-11 September 2012 • Toulouse, France
Jointly organised by ESTRO and the Institut Claudius Regaud



Elizabeth C. J. Moyal

↳ AS THE MEETING GETS CLOSER, WE HEAR MORE ABOUT THE SYMPOSIUM FROM ELIZABETH C. J. MOYAL WHO CO-CHAIRS THE SYMPOSIUM WITH V. VALENTINI

Why does Novel Targeting Drugs and Radiotherapy need its own conference?

The relapse of several tumours after radiotherapy treatment is in part due to their intra-cellular radioresistance but also their micro-environmental radioresistance. The complexity of the biology of these tumours and the presence of numerous cross-talks between the pathways of these different growth factors can in part be responsible for the negative results obtained in clinical trials associating radiotherapy and targeted drugs or chemotherapy designed without previous *in vitro* and *in vivo* studies to validate the proof of concept of a specific target as a key factor of radioresistance. The Novel Targeting drugs and radiotherapy conference is the meeting specifically dedicated to translational research describing the latest results regarding validation of interesting targets controlling radioresistance, as well as the radiosensitising effect of their inhibition in pre-clinical studies and then in clinical trials integrating metabolic or functional imaging and surrogate markers to better understand the mechanism of action of these associations.

In your view what are the highlights of the meeting this year?

The symposium will highlight the emerging opportunities for the more effective combination of radiation and drugs as well as ongoing biologically driven trials combining radiotherapy with targeted therapies in different diseases, molecular imaging as prognostic or predictive tools of response to targeted drugs and radiotherapy as well as development of such imaging using nanotechnology. Conferences on the involvement of tumour stem cells in radioresistance as well as functional genomic approaches to novel target discovery in radiotherapy will be also presented.

So who should attend the conference?

Radiation oncologists, academic researchers and researchers from the industry, researchers in metabolic and functional imaging will all find areas of interest in the programme for this meeting.

And finally, what can delegates look forward to on the social programme?


The delegates will have the opportunity to come together for a dinner in a lovely venue - either the Natural History museum or the Aerospace museum. This will enable useful exchanges and discussions between colleagues from many different centres. ■

Where will the meeting be held and how often is it held?

The meeting will be held at the Toulouse Mediathèque, Toulouse, France and takes place every two years.

How many delegates do you expect to attend?

300 delegates.



DEADLINES

- Abstract submission: 11 May 2012
- Early registration: 22 May 2012
- Late registration: 6 August 2012
- Desk registration: as of 7 August 2012